SCHEMBL13885

SCHEMBL13885

Cc1nc(=O)c(-c2ccc(CNCCCN)cc2)c[nH]1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.41
MC4R P32245 2/20 0.40
MC5R P33032 2/20 0.40
MC3R P41968 1/20 0.40
HRH4 Q9H3N8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
PDCD1 Q15116 2/20 0.38
CD274 Q9NZQ7 2/20 0.38
VSIR Q9H7M9 3/20 0.37
CHRM2 P08172 1/20 0.36
MC1R Q01726 1/20 0.35
EP300 Q09472 1/20 0.35
PRMT3 O60678 1/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
PRMT1 Q99873 1/20 0.33
PRMT8 Q9NR22 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14850266 0.85 EP300 (0.40) PARP1MC4RMC5RMC3RHRH4
SCHEMBL13547 0.84 PARP1 (0.37) PARP1HRH4HRH3PDCD1CD274
SCHEMBL19719376 0.83 PARP1 (0.38) PARP1MC4RMC5RMC3RHRH4
SCHEMBL17354302 0.82 CHRM2 (0.39) PARP1MC4RMC5RMC3RPDCD1
SCHEMBL19719304 0.82 PARP1 (0.39) PARP1MC4RMC5RMC3RHRH4
SCHEMBL13770 0.80 AKT2 (0.46) PARP1HRH3CD274
SCHEMBL17354133 0.77 KDR (0.41) VSIR
SCHEMBL17354352 0.76 PLK4 (0.33) PARP1MC4RMC5RMC3RPDCD1
SCHEMBL14850241 0.76 SCN8A (0.35) PARP1MC4RMC5RMC3REP300
SCHEMBL17354145 0.75 HDAC3 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
WO-2011047323-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT PARP1 1324/4885MC4R 2989/4885MC5R 3036/4885
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT PARP1 1324/4885MC4R 2989/4885MC5R 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.